Leerink Swann reaffirmed their positive rating on shares of Intercept Pharmaceuticals Inc. (NASDAQ:ICPT) in a report released on Friday morning. The brokerage currently has a $159.00 target price on the biopharmaceutical company’s stock.

ICPT has been the topic of a number of other research reports. Wedbush reiterated an outperform rating and set a $239.00 price objective on shares of Intercept Pharmaceuticals in a research report on Monday, July 25th. Credit Suisse Group AG reiterated a buy rating and set a $200.00 price objective on shares of Intercept Pharmaceuticals in a research report on Friday, August 5th. Vetr cut shares of Intercept Pharmaceuticals from a sell rating to a strong sell rating and set a $81.50 price objective on the stock. in a research report on Monday, August 8th. Oppenheimer Holdings Inc. cut their price objective on shares of Intercept Pharmaceuticals from $265.00 to $250.00 and set an outperform rating on the stock in a research report on Friday, August 5th. Finally, Cantor Fitzgerald reiterated a sell rating and set a $60.00 price objective on shares of Intercept Pharmaceuticals in a research report on Monday, August 8th. Five equities research analysts have rated the stock with a sell rating, four have issued a hold rating and eleven have given a buy rating to the company. The company presently has a consensus rating of Hold and a consensus price target of $178.62.

Analyst Recommendations for Intercept Pharmaceuticals (NASDAQ:ICPT)

Intercept Pharmaceuticals (NASDAQ:ICPT) traded down 3.361% on Friday, reaching $137.681. The company’s stock had a trading volume of 200,618 shares. The firm’s market cap is $3.40 billion. Intercept Pharmaceuticals has a 12 month low of $89.76 and a 12 month high of $217.99. The firm’s 50 day moving average is $155.48 and its 200-day moving average is $151.28.

Intercept Pharmaceuticals (NASDAQ:ICPT) last posted its quarterly earnings data on Thursday, August 4th. The biopharmaceutical company reported ($3.14) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($3.69) by $0.55. Intercept Pharmaceuticals had a negative net margin of 5,003.95% and a negative return on equity of 50.58%. The business had revenue of $5.52 million for the quarter, compared to analysts’ expectations of $1.72 million. During the same quarter in the previous year, the business posted ($1.99) earnings per share. The business’s revenue was up 1140.4% compared to the same quarter last year. On average, equities research analysts anticipate that Intercept Pharmaceuticals will post ($16.31) EPS for the current year.

In related news, CEO Mark Pruzanski sold 35,000 shares of the stock in a transaction that occurred on Tuesday, September 20th. The shares were sold at an average price of $165.00, for a total value of $5,775,000.00. Following the transaction, the chief executive officer now owns 579,314 shares in the company, valued at approximately $95,586,810. The sale was disclosed in a filing with the SEC, which is available through this link. Also, insider Lisa Bright sold 246 shares of the stock in a transaction that occurred on Thursday, August 25th. The stock was sold at an average price of $159.00, for a total transaction of $39,114.00. Following the completion of the transaction, the insider now owns 18,460 shares in the company, valued at approximately $2,935,140. The disclosure for this sale can be found here. 9.20% of the stock is currently owned by corporate insiders.

Institutional investors have recently modified their holdings of the company. Aperio Group LLC increased its position in shares of Intercept Pharmaceuticals by 31.2% in the first quarter. Aperio Group LLC now owns 2,152 shares of the biopharmaceutical company’s stock valued at $276,000 after buying an additional 512 shares during the period. BlackRock Inc. increased its position in shares of Intercept Pharmaceuticals by 301.5% in the first quarter. BlackRock Inc. now owns 1,915 shares of the biopharmaceutical company’s stock valued at $246,000 after buying an additional 1,438 shares during the period. BlackRock Group LTD increased its position in shares of Intercept Pharmaceuticals by 20.1% in the first quarter. BlackRock Group LTD now owns 13,074 shares of the biopharmaceutical company’s stock valued at $1,680,000 after buying an additional 2,188 shares during the period. BlackRock Fund Advisors increased its position in shares of Intercept Pharmaceuticals by 7.2% in the first quarter. BlackRock Fund Advisors now owns 467,272 shares of the biopharmaceutical company’s stock valued at $60,030,000 after buying an additional 31,289 shares during the period. Finally, State Street Corp increased its position in shares of Intercept Pharmaceuticals by 27.5% in the first quarter. State Street Corp now owns 521,407 shares of the biopharmaceutical company’s stock valued at $66,990,000 after buying an additional 112,431 shares during the period. Institutional investors own 81.83% of the company’s stock.

About Intercept Pharmaceuticals

Intercept Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat non-viral, progressive liver diseases. The Company’s product candidates have the potential to treat orphan and more prevalent diseases for which there are limited therapeutic solutions.

5 Day Chart for NASDAQ:ICPT

Receive News & Stock Ratings for Intercept Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intercept Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.